Pharmerica Corporation shares had a trading volume of 456K in the last trading session. Volume was up 96.10% over the stocks average daily volume.
Traders are more bullish of late if you evaluate the downtick in short interest. The firm recorded a fall in short interest of -34.15% between September 29, 2017 and October 13, 2017. Short shares fell from 387,692 to 255,305 over that timeframe. The days to cover decreased to 1.0 and the percentage of shorted shares is 0.01% as of October 13.
These funds have shifted positions in (PMC). Strs Ohio divested its ownership by selling 2,600 shares a decrease of 8.4% as of 09/30/2017. Strs Ohio owns 28,400 shares valued at $832,000. The value of the position overall is up by 2.3%. As of the end of the quarter Nationwide Fund Advisors had sold a total of 425 shares trimming its holdings by 2.0%. The value of the company’s investment in Pharmerica Corporation increased from $560,000 to $613,000 increasing 9.5% since the last quarter.
Parkside Financial Bank & Trust downsized its position by shedding 85 shares a decrease of 6.6% in the quarter. Parkside Financial Bank & Trust currently owns 1,195 shares worth $35,000. The total value of its holdings increased 2.9%. Aperio Group, LLC grew its investment by buying 1,152 shares an increase of 14.5%. Aperio Group, LLC now controls 9,100 shares with a value of $267,000. The total value of its holdings increased 27.8%.
On August 3 the company was rated “Underperform” according to a Barrington Research report which was a cut from the previous “Outperform” rating. On August 4 the company was downgraded from “Outperform” to “Neutral” by analysts at Credit Suisse.
The company is up since yesterday’s close of $29.30. Shares are trading at $29.30 which is a tad above $29.16, the stock’s 50 day moving average and which is just a bit higher than the 200 day moving average of $26.97. The 50 day moving average was up $0.14 or +0.49% and the 200 day average went up $2.33 or +8.64%.
The P/E ratio is currently 39.70 and market cap is 911.85M. As of the last earnings report the EPS was $0.74 and is projected to be $1.94 for the current year with 31,121,000 shares outstanding. Analysts expect next quarter’s EPS to be $0.55 and the next full year EPS is anticipated to be $2.19.
PharMerica Corporation, launched on October 23, 2006, is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. The Business’s segments include institutional pharmacy, specialty infusion services and specialty oncology pharmacy. The Business’s institutional pharmacy segment provides pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals and other long-term alternative care settings. The Business’s specialty infusion services segment provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities, hospice and outside of hospital or nursing home settings. The Business’s specialty oncology pharmacy segment provides dispensing of oncology drugs, care management and other related services to patients, oncology practices and hospitals..